ArticleVeterinary world2025
Comparative protective effects of rosuvastatin and ramipril against doxorubicin-induced testicular toxicity in rats: A multimodal evaluation of oxidative stress and reproductive parameters.
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Doxorubicin, a widely used chemotherapeutic agent, is associated with reproductive toxicity due to its induction of oxidative stress and testicular damage. Emerging evidence suggests that rosuvastatin and ramipril may possess antioxidant and cytoprotective properties beyond their conventional uses. However, their comparative efficacy in preventing doxorubicin-induced testicular toxicity remains unclear. This study aimed to evaluate and compare the protective effects of rosuvastatin and ramipril on testicular function, oxidative stress markers, and reproductive outcomes in a rat model of doxorubicin-induced testicular toxicity. Materials and Methods: Twenty-four male: Wistar rats were randomly allocated into four groups: Control, doxorubicin-only, rosuvastatin + doxorubicin, and ramipril + doxorubicin. Doxorubicin (5 mg/kg, intraperitoneal) was administered on days 7, 14, and 21, while rosuvastatin or ramipril (5 mg/kg/day, oral) was given for 21 days. On day 45, evaluations included testicular index, sperm count and motility, serum testosterone levels, oxidative stress markers (malondialdehyde [MDA], nitric oxide [NO], glutathione [GSH]), and histopathological analysis using Johnsen scoring. Results: Both rosuvastatin and ramipril significantly restored the testicular index compared to the doxorubicin group (p < 0.05). Ramipril markedly increased serum testosterone, GSH, and NO levels while reducing MDA. Sperm motility and count showed partial improvement, notably in the ramipril group. Histopathological alterations were attenuated in both treatment groups, with improved Johnsen scores and reduced architectural disruption. Conclusion: Ramipril and rosuvastatin mitigate doxorubicin-induced testicular toxicity through antioxidant mechanisms. Ramipril demonstrated superior efficacy in preserving reproductive hormone levels and sperm function. These findings highlight its potential as a fertility-protective agent during chemotherapy. Further long-term and mechanistic studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.